Philip Reigan
Concepts (387)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thymidine Phosphorylase | 7 | 2022 | 12 | 2.510 |
Why?
| Antineoplastic Agents | 16 | 2020 | 1891 | 2.140 |
Why?
| Ribosomal Protein S6 Kinases, 90-kDa | 4 | 2021 | 13 | 2.080 |
Why?
| Protein Kinase Inhibitors | 8 | 2021 | 788 | 1.930 |
Why?
| Pyrimidines | 6 | 2021 | 376 | 1.870 |
Why?
| Protein-Tyrosine Kinases | 6 | 2019 | 394 | 1.650 |
Why?
| Nuclear Proteins | 6 | 2018 | 594 | 1.500 |
Why?
| Cell Cycle Proteins | 5 | 2018 | 555 | 1.470 |
Why?
| Enzyme Inhibitors | 9 | 2021 | 758 | 1.320 |
Why?
| Glioblastoma | 3 | 2022 | 251 | 1.200 |
Why?
| STAT3 Transcription Factor | 3 | 2022 | 174 | 1.160 |
Why?
| Pyrazoles | 4 | 2018 | 362 | 1.040 |
Why?
| Neoplasms | 5 | 2023 | 2111 | 1.030 |
Why?
| Models, Molecular | 25 | 2021 | 1391 | 1.020 |
Why?
| Pyrroles | 2 | 2021 | 185 | 0.930 |
Why?
| Prodrugs | 4 | 2007 | 43 | 0.840 |
Why?
| Pyrimidinones | 4 | 2018 | 86 | 0.790 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 8 | 2011 | 31 | 0.790 |
Why?
| Purines | 1 | 2021 | 159 | 0.710 |
Why?
| Pteridines | 1 | 2020 | 21 | 0.700 |
Why?
| Cell Survival | 8 | 2022 | 1026 | 0.680 |
Why?
| Drug Resistance, Neoplasm | 4 | 2021 | 638 | 0.670 |
Why?
| Structure-Activity Relationship | 10 | 2020 | 510 | 0.670 |
Why?
| Small Molecule Libraries | 2 | 2016 | 81 | 0.660 |
Why?
| AMP-Activated Protein Kinases | 1 | 2020 | 175 | 0.650 |
Why?
| Indolequinones | 5 | 2011 | 5 | 0.650 |
Why?
| Aldehydes | 8 | 2014 | 146 | 0.600 |
Why?
| HSP90 Heat-Shock Proteins | 5 | 2011 | 43 | 0.600 |
Why?
| Protein Binding | 12 | 2021 | 1919 | 0.590 |
Why?
| Brain Neoplasms | 3 | 2020 | 979 | 0.590 |
Why?
| Medulloblastoma | 2 | 2016 | 172 | 0.560 |
Why?
| Cell Line, Tumor | 18 | 2022 | 2749 | 0.550 |
Why?
| Glutamate-Cysteine Ligase | 2 | 2013 | 17 | 0.550 |
Why?
| Xanthine Oxidase | 2 | 2007 | 72 | 0.530 |
Why?
| Protein Isoforms | 1 | 2017 | 339 | 0.530 |
Why?
| Benzoquinones | 4 | 2011 | 44 | 0.520 |
Why?
| Uracil | 3 | 2021 | 31 | 0.500 |
Why?
| Cisplatin | 1 | 2016 | 263 | 0.480 |
Why?
| Isoxazoles | 5 | 2023 | 56 | 0.480 |
Why?
| Hydroquinones | 3 | 2011 | 27 | 0.460 |
Why?
| Lactams, Macrocyclic | 3 | 2011 | 46 | 0.450 |
Why?
| Deoxyribose | 1 | 2013 | 5 | 0.450 |
Why?
| Drug Screening Assays, Antitumor | 5 | 2020 | 180 | 0.430 |
Why?
| Glutathione | 2 | 2011 | 303 | 0.430 |
Why?
| Humans | 57 | 2024 | 115890 | 0.390 |
Why?
| Molecular Structure | 5 | 2020 | 447 | 0.380 |
Why?
| Molecular Docking Simulation | 6 | 2023 | 101 | 0.370 |
Why?
| Catalytic Domain | 5 | 2021 | 201 | 0.340 |
Why?
| Protein Conformation | 4 | 2021 | 822 | 0.340 |
Why?
| Cell Line | 5 | 2022 | 2655 | 0.330 |
Why?
| Cell Proliferation | 10 | 2020 | 2196 | 0.330 |
Why?
| Glucose | 2 | 2013 | 904 | 0.330 |
Why?
| Imidazoles | 3 | 2021 | 215 | 0.320 |
Why?
| Molecular Targeted Therapy | 3 | 2016 | 348 | 0.320 |
Why?
| Aldehyde Dehydrogenase | 3 | 2014 | 129 | 0.310 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 190 | 0.310 |
Why?
| Signal Transduction | 6 | 2022 | 4525 | 0.300 |
Why?
| Amides | 2 | 2020 | 89 | 0.300 |
Why?
| Growth Inhibitors | 1 | 2007 | 45 | 0.290 |
Why?
| Pancreatic Neoplasms | 4 | 2009 | 721 | 0.280 |
Why?
| Thyroid Neoplasms | 2 | 2021 | 261 | 0.280 |
Why?
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 399 | 0.280 |
Why?
| src Homology Domains | 2 | 2016 | 33 | 0.270 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2023 | 448 | 0.250 |
Why?
| Binding Sites | 6 | 2018 | 1183 | 0.250 |
Why?
| Molecular Dynamics Simulation | 3 | 2023 | 208 | 0.250 |
Why?
| Animals | 27 | 2022 | 32120 | 0.240 |
Why?
| Pyrrolidines | 1 | 2004 | 56 | 0.240 |
Why?
| G-Quadruplexes | 2 | 2022 | 15 | 0.240 |
Why?
| Giardia lamblia | 1 | 2024 | 21 | 0.230 |
Why?
| Thymidine | 2 | 2022 | 58 | 0.220 |
Why?
| Rifabutin | 3 | 2008 | 5 | 0.220 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2023 | 40 | 0.210 |
Why?
| DNA | 3 | 2016 | 1358 | 0.210 |
Why?
| Liver Diseases, Alcoholic | 2 | 2014 | 85 | 0.210 |
Why?
| Ear Diseases | 1 | 2022 | 13 | 0.200 |
Why?
| Amino Acid Transport System ASC | 1 | 2022 | 10 | 0.200 |
Why?
| K562 Cells | 2 | 2020 | 72 | 0.200 |
Why?
| Virus Internalization | 1 | 2022 | 41 | 0.200 |
Why?
| Models, Chemical | 1 | 2023 | 264 | 0.200 |
Why?
| Minor Histocompatibility Antigens | 1 | 2022 | 41 | 0.200 |
Why?
| Drug Synergism | 3 | 2021 | 316 | 0.200 |
Why?
| Catalysis | 3 | 2013 | 299 | 0.200 |
Why?
| Quinone Reductases | 2 | 2011 | 15 | 0.190 |
Why?
| Fluorouracil | 1 | 2022 | 151 | 0.190 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2022 | 115 | 0.190 |
Why?
| Maneb | 1 | 2020 | 7 | 0.190 |
Why?
| Receptors, Androgen | 1 | 2022 | 132 | 0.190 |
Why?
| Heterocyclic Compounds | 1 | 2020 | 20 | 0.180 |
Why?
| Lipoprotein Lipase | 1 | 2020 | 55 | 0.180 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 145 | 0.180 |
Why?
| Dose-Response Relationship, Drug | 3 | 2020 | 1868 | 0.180 |
Why?
| Mice | 17 | 2022 | 15073 | 0.180 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 163 | 0.180 |
Why?
| Neovascularization, Pathologic | 1 | 2022 | 283 | 0.180 |
Why?
| Fluorescence | 1 | 2020 | 153 | 0.180 |
Why?
| Polymorphism, Genetic | 2 | 2014 | 632 | 0.180 |
Why?
| Amino Acid Sequence | 8 | 2014 | 2000 | 0.160 |
Why?
| Adenocarcinoma, Follicular | 1 | 2019 | 34 | 0.160 |
Why?
| Chromatography, High Pressure Liquid | 5 | 2013 | 477 | 0.160 |
Why?
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 34 | 0.160 |
Why?
| Protein Carbonylation | 3 | 2013 | 52 | 0.160 |
Why?
| Enzyme Assays | 1 | 2018 | 22 | 0.160 |
Why?
| CDC2 Protein Kinase | 1 | 2018 | 25 | 0.160 |
Why?
| Receptors, Metabotropic Glutamate | 1 | 2018 | 35 | 0.160 |
Why?
| Neoplastic Stem Cells | 1 | 2022 | 330 | 0.160 |
Why?
| Pyridazines | 1 | 2018 | 46 | 0.160 |
Why?
| Escherichia coli | 4 | 2006 | 730 | 0.150 |
Why?
| Phosphorylation | 3 | 2018 | 1560 | 0.150 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 228 | 0.150 |
Why?
| Antigens, Neoplasm | 2 | 2011 | 224 | 0.150 |
Why?
| Dihydropyridines | 1 | 2017 | 14 | 0.150 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2022 | 531 | 0.150 |
Why?
| Glucocorticoids | 1 | 2022 | 551 | 0.150 |
Why?
| Glycoproteins | 2 | 2011 | 308 | 0.150 |
Why?
| Cyclic S-Oxides | 1 | 2016 | 1 | 0.140 |
Why?
| Niclosamide | 1 | 2016 | 1 | 0.140 |
Why?
| Oncogene Proteins, Fusion | 1 | 2019 | 178 | 0.140 |
Why?
| Lysine | 2 | 2023 | 243 | 0.140 |
Why?
| Fluorescence Polarization | 1 | 2016 | 35 | 0.140 |
Why?
| MicroRNAs | 1 | 2023 | 610 | 0.140 |
Why?
| Parkinson Disease | 1 | 2020 | 328 | 0.140 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 41 | 0.140 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.140 |
Why?
| Antioxidants | 2 | 2011 | 533 | 0.140 |
Why?
| Antiviral Agents | 1 | 2022 | 648 | 0.140 |
Why?
| Immunity, Innate | 1 | 2022 | 733 | 0.140 |
Why?
| Molecular Sequence Data | 7 | 2014 | 2793 | 0.130 |
Why?
| Quantitative Structure-Activity Relationship | 1 | 2015 | 13 | 0.130 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2013 | 138 | 0.130 |
Why?
| Oxidation-Reduction | 5 | 2020 | 933 | 0.130 |
Why?
| Crystallography, X-Ray | 5 | 2017 | 408 | 0.130 |
Why?
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 8 | 0.130 |
Why?
| Alzheimer Disease | 1 | 2020 | 450 | 0.130 |
Why?
| Drug Design | 1 | 2016 | 156 | 0.130 |
Why?
| Cells, Cultured | 3 | 2020 | 3916 | 0.130 |
Why?
| HeLa Cells | 1 | 2016 | 568 | 0.120 |
Why?
| Retinaldehyde | 1 | 2014 | 6 | 0.120 |
Why?
| Allosteric Regulation | 3 | 2023 | 84 | 0.120 |
Why?
| Membrane Proteins | 2 | 2011 | 1033 | 0.120 |
Why?
| Acetaldehyde | 1 | 2014 | 20 | 0.120 |
Why?
| Drug Discovery | 1 | 2016 | 124 | 0.120 |
Why?
| Sulfhydryl Compounds | 2 | 2020 | 178 | 0.120 |
Why?
| Recombinant Proteins | 5 | 2011 | 1243 | 0.120 |
Why?
| DNA Repair | 1 | 2016 | 192 | 0.120 |
Why?
| Mass Spectrometry | 4 | 2012 | 661 | 0.120 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 794 | 0.120 |
Why?
| Pituitary Neoplasms | 1 | 2015 | 157 | 0.120 |
Why?
| Computer Simulation | 4 | 2014 | 887 | 0.120 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2014 | 92 | 0.110 |
Why?
| Heat-Shock Proteins | 1 | 2014 | 113 | 0.110 |
Why?
| Mammary Glands, Animal | 2 | 2011 | 116 | 0.110 |
Why?
| Fatty Liver, Alcoholic | 1 | 2013 | 16 | 0.110 |
Why?
| Protein Folding | 2 | 2014 | 242 | 0.110 |
Why?
| Adenosine Triphosphatases | 1 | 2014 | 156 | 0.110 |
Why?
| Lactation | 2 | 2011 | 149 | 0.110 |
Why?
| Inflammation | 2 | 2022 | 2503 | 0.110 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2014 | 147 | 0.110 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2013 | 83 | 0.110 |
Why?
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 25 | 0.110 |
Why?
| Cell Cycle | 2 | 2014 | 546 | 0.110 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1359 | 0.110 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 313 | 0.110 |
Why?
| Gene Expression Regulation | 3 | 2013 | 2362 | 0.110 |
Why?
| Gout | 1 | 2013 | 37 | 0.110 |
Why?
| Electron Transport Complex I | 1 | 2012 | 34 | 0.100 |
Why?
| Status Epilepticus | 1 | 2012 | 34 | 0.100 |
Why?
| PTEN Phosphohydrolase | 1 | 2013 | 141 | 0.100 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2012 | 63 | 0.100 |
Why?
| Glutathione Reductase | 1 | 2011 | 21 | 0.100 |
Why?
| Acridines | 1 | 2011 | 7 | 0.100 |
Why?
| Glutathione Peroxidase | 1 | 2011 | 42 | 0.100 |
Why?
| Apoptosis | 6 | 2021 | 2377 | 0.100 |
Why?
| DNA Topoisomerases, Type II | 1 | 2011 | 45 | 0.100 |
Why?
| Glutathione Transferase | 1 | 2011 | 96 | 0.100 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 389 | 0.100 |
Why?
| Flavoproteins | 1 | 2011 | 7 | 0.100 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 195 | 0.100 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2021 | 703 | 0.100 |
Why?
| Glycolipids | 1 | 2011 | 37 | 0.090 |
Why?
| Transcriptional Activation | 1 | 2013 | 341 | 0.090 |
Why?
| Myocytes, Cardiac | 1 | 2015 | 456 | 0.090 |
Why?
| Mitochondria, Liver | 1 | 2011 | 66 | 0.090 |
Why?
| Organelles | 1 | 2011 | 51 | 0.090 |
Why?
| Hydrogen Peroxide | 1 | 2012 | 286 | 0.090 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 96 | 0.090 |
Why?
| Indoles | 2 | 2015 | 309 | 0.090 |
Why?
| Sirtuin 3 | 1 | 2011 | 52 | 0.090 |
Why?
| Brain | 2 | 2012 | 2382 | 0.090 |
Why?
| Carcinoma, Hepatocellular | 1 | 2012 | 224 | 0.090 |
Why?
| Breast Neoplasms | 2 | 2020 | 1870 | 0.090 |
Why?
| Superoxide Dismutase | 1 | 2012 | 332 | 0.090 |
Why?
| Milk | 1 | 2011 | 124 | 0.090 |
Why?
| Enzyme Activation | 2 | 2013 | 791 | 0.090 |
Why?
| Protein Processing, Post-Translational | 1 | 2012 | 400 | 0.090 |
Why?
| Cell Movement | 1 | 2014 | 868 | 0.090 |
Why?
| Oxidative Stress | 2 | 2014 | 1096 | 0.090 |
Why?
| Kinetics | 1 | 2013 | 1560 | 0.090 |
Why?
| Phospholipids | 1 | 2011 | 202 | 0.080 |
Why?
| Adenosine Triphosphate | 1 | 2011 | 430 | 0.080 |
Why?
| Thioredoxin-Disulfide Reductase | 1 | 2009 | 14 | 0.080 |
Why?
| Peroxiredoxin VI | 1 | 2008 | 5 | 0.080 |
Why?
| Tumor Cells, Cultured | 3 | 2022 | 850 | 0.080 |
Why?
| Protein Structure, Tertiary | 4 | 2014 | 804 | 0.080 |
Why?
| Down-Regulation | 1 | 2011 | 605 | 0.080 |
Why?
| DNA-Binding Proteins | 2 | 2013 | 1319 | 0.080 |
Why?
| Lipid Metabolism | 1 | 2011 | 449 | 0.080 |
Why?
| Mutation | 4 | 2021 | 3369 | 0.080 |
Why?
| Protein Interaction Domains and Motifs | 3 | 2013 | 136 | 0.080 |
Why?
| Cross-Linking Reagents | 1 | 2008 | 182 | 0.080 |
Why?
| Quinones | 1 | 2007 | 10 | 0.080 |
Why?
| Spectrophotometry, Infrared | 1 | 2007 | 45 | 0.070 |
Why?
| Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
| NF-kappa B p50 Subunit | 1 | 2007 | 25 | 0.070 |
Why?
| Energy Metabolism | 1 | 2012 | 712 | 0.070 |
Why?
| Cell Membrane | 1 | 2011 | 682 | 0.070 |
Why?
| Galactosides | 1 | 2006 | 3 | 0.070 |
Why?
| Anti-Bacterial Agents | 2 | 2024 | 1486 | 0.070 |
Why?
| beta-Galactosidase | 1 | 2006 | 63 | 0.070 |
Why?
| Substrate Specificity | 3 | 2014 | 356 | 0.070 |
Why?
| RNA, Messenger | 2 | 2024 | 2581 | 0.070 |
Why?
| Arginine | 3 | 2013 | 241 | 0.070 |
Why?
| Carcinoma | 1 | 2007 | 200 | 0.060 |
Why?
| Nitroimidazoles | 1 | 2005 | 6 | 0.060 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2007 | 484 | 0.060 |
Why?
| Computational Biology | 1 | 2008 | 528 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 3 | 2011 | 167 | 0.060 |
Why?
| Biological Availability | 1 | 2005 | 119 | 0.060 |
Why?
| Emetine | 1 | 2024 | 7 | 0.060 |
Why?
| Aldehyde Dehydrogenase, Mitochondrial | 2 | 2014 | 32 | 0.060 |
Why?
| Mice, Nude | 2 | 2021 | 639 | 0.060 |
Why?
| Polycomb-Group Proteins | 1 | 2023 | 29 | 0.060 |
Why?
| Mice, Inbred C57BL | 4 | 2014 | 4767 | 0.060 |
Why?
| Cryoelectron Microscopy | 1 | 2024 | 144 | 0.050 |
Why?
| Peptides | 2 | 2023 | 862 | 0.050 |
Why?
| Insulin Resistance | 1 | 2011 | 1077 | 0.050 |
Why?
| Ribosomes | 1 | 2024 | 144 | 0.050 |
Why?
| Benzamides | 1 | 2023 | 169 | 0.050 |
Why?
| Disease Models, Animal | 3 | 2022 | 3583 | 0.050 |
Why?
| Exoribonucleases | 1 | 2023 | 40 | 0.050 |
Why?
| Molecular Conformation | 2 | 2015 | 138 | 0.050 |
Why?
| Alcohols | 1 | 2022 | 29 | 0.050 |
Why?
| Phospholipase C beta | 1 | 2022 | 26 | 0.050 |
Why?
| Ethanol | 3 | 2012 | 549 | 0.050 |
Why?
| Mesocricetus | 1 | 2022 | 30 | 0.050 |
Why?
| Stress, Physiological | 2 | 2015 | 397 | 0.050 |
Why?
| Hep G2 Cells | 2 | 2013 | 61 | 0.050 |
Why?
| Ear | 1 | 2022 | 32 | 0.050 |
Why?
| Peptide Mapping | 2 | 2012 | 59 | 0.050 |
Why?
| High-Throughput Screening Assays | 1 | 2023 | 123 | 0.050 |
Why?
| Serine Endopeptidases | 1 | 2022 | 102 | 0.050 |
Why?
| Sequence Alignment | 2 | 2012 | 328 | 0.050 |
Why?
| Oximes | 1 | 2021 | 17 | 0.050 |
Why?
| Perilipin-2 | 2 | 2011 | 36 | 0.050 |
Why?
| Oxidative Phosphorylation | 1 | 2022 | 155 | 0.050 |
Why?
| Angiogenesis Inhibitors | 1 | 2003 | 216 | 0.050 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 94 | 0.050 |
Why?
| Neural Crest | 1 | 2022 | 117 | 0.050 |
Why?
| Indazoles | 1 | 2021 | 58 | 0.050 |
Why?
| Cell-Free System | 2 | 2011 | 47 | 0.050 |
Why?
| Antibodies, Monoclonal | 1 | 2006 | 1262 | 0.040 |
Why?
| Viral Load | 1 | 2022 | 406 | 0.040 |
Why?
| Blotting, Western | 2 | 2013 | 1153 | 0.040 |
Why?
| HEK293 Cells | 2 | 2013 | 604 | 0.040 |
Why?
| Lipoproteins | 1 | 2020 | 162 | 0.040 |
Why?
| Carbon | 1 | 2020 | 163 | 0.040 |
Why?
| T-Lymphocytes | 1 | 2007 | 1754 | 0.040 |
Why?
| MAP Kinase Signaling System | 1 | 2021 | 275 | 0.040 |
Why?
| Microglia | 1 | 2020 | 205 | 0.040 |
Why?
| Tandem Mass Spectrometry | 2 | 2013 | 416 | 0.040 |
Why?
| Female | 8 | 2022 | 60076 | 0.040 |
Why?
| Genomics | 2 | 2014 | 640 | 0.040 |
Why?
| Piperazines | 1 | 2021 | 313 | 0.040 |
Why?
| Neoplasm Transplantation | 1 | 2019 | 235 | 0.040 |
Why?
| Triglycerides | 1 | 2020 | 470 | 0.040 |
Why?
| Amyloid beta-Peptides | 1 | 2020 | 194 | 0.040 |
Why?
| Drug Resistance, Multiple | 1 | 2017 | 19 | 0.040 |
Why?
| Child | 1 | 2016 | 18550 | 0.040 |
Why?
| Dimerization | 1 | 2017 | 177 | 0.040 |
Why?
| Models, Biological | 2 | 2014 | 1647 | 0.030 |
Why?
| Rats, Sprague-Dawley | 2 | 2012 | 2262 | 0.030 |
Why?
| Nitroglycerin | 1 | 2014 | 22 | 0.030 |
Why?
| Adult | 1 | 2016 | 30814 | 0.030 |
Why?
| Circular Dichroism | 1 | 2015 | 135 | 0.030 |
Why?
| Male | 6 | 2022 | 56123 | 0.030 |
Why?
| Spectrophotometry, Ultraviolet | 1 | 2014 | 75 | 0.030 |
Why?
| Unfolded Protein Response | 1 | 2014 | 45 | 0.030 |
Why?
| Phenotype | 1 | 2022 | 2858 | 0.030 |
Why?
| Calorimetry | 1 | 2014 | 62 | 0.030 |
Why?
| Magnesium | 1 | 2014 | 145 | 0.030 |
Why?
| Macrophages | 1 | 2020 | 1281 | 0.030 |
Why?
| Lung | 2 | 2022 | 3685 | 0.030 |
Why?
| Sequence Homology, Amino Acid | 1 | 2014 | 352 | 0.030 |
Why?
| Cell Cycle Checkpoints | 1 | 2013 | 84 | 0.030 |
Why?
| Retinoid X Receptors | 1 | 2013 | 39 | 0.030 |
Why?
| Caco-2 Cells | 1 | 2013 | 66 | 0.030 |
Why?
| RNA Splice Sites | 1 | 2013 | 32 | 0.030 |
Why?
| Tumor Microenvironment | 1 | 2015 | 424 | 0.030 |
Why?
| Hyperuricemia | 1 | 2013 | 43 | 0.030 |
Why?
| Telomere | 1 | 2015 | 205 | 0.030 |
Why?
| Synaptosomes | 1 | 2012 | 12 | 0.030 |
Why?
| Biotinylation | 1 | 2012 | 29 | 0.030 |
Why?
| Kainic Acid | 1 | 2012 | 31 | 0.030 |
Why?
| Fishes | 1 | 2013 | 81 | 0.030 |
Why?
| Anilino Naphthalenesulfonates | 1 | 2012 | 10 | 0.030 |
Why?
| Excitatory Amino Acid Agonists | 1 | 2012 | 37 | 0.030 |
Why?
| Methyltransferases | 1 | 2013 | 61 | 0.030 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 238 | 0.030 |
Why?
| Electron Transport Complex IV | 1 | 2012 | 53 | 0.030 |
Why?
| Anura | 1 | 2012 | 42 | 0.030 |
Why?
| Rats | 2 | 2012 | 5035 | 0.030 |
Why?
| Sulfonamides | 1 | 2015 | 447 | 0.030 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 100 | 0.030 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2012 | 45 | 0.030 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2013 | 123 | 0.030 |
Why?
| Molecular Weight | 1 | 2012 | 335 | 0.030 |
Why?
| Endoplasmic Reticulum | 1 | 2014 | 236 | 0.030 |
Why?
| Ubiquitination | 1 | 2012 | 86 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2012 | 99 | 0.030 |
Why?
| Immunoprecipitation | 1 | 2012 | 154 | 0.030 |
Why?
| Genome, Human | 1 | 2014 | 374 | 0.020 |
Why?
| Inhibitory Concentration 50 | 1 | 2011 | 78 | 0.020 |
Why?
| Amination | 1 | 2011 | 2 | 0.020 |
Why?
| Nucleic Acid Conformation | 1 | 2015 | 664 | 0.020 |
Why?
| Alkylation | 1 | 2011 | 19 | 0.020 |
Why?
| Chromatography, Liquid | 1 | 2013 | 346 | 0.020 |
Why?
| Oxidants | 1 | 2012 | 113 | 0.020 |
Why?
| Embryo, Mammalian | 1 | 2012 | 215 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2015 | 1643 | 0.020 |
Why?
| Protein Subunits | 1 | 2012 | 205 | 0.020 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2013 | 198 | 0.020 |
Why?
| Lipid Droplets | 1 | 2011 | 21 | 0.020 |
Why?
| Binding, Competitive | 1 | 2011 | 200 | 0.020 |
Why?
| Metabolic Networks and Pathways | 1 | 2012 | 167 | 0.020 |
Why?
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 60 | 0.020 |
Why?
| Cloning, Molecular | 1 | 2012 | 522 | 0.020 |
Why?
| DNA Primers | 1 | 2012 | 513 | 0.020 |
Why?
| Ligands | 1 | 2013 | 568 | 0.020 |
Why?
| Mammary Glands, Human | 1 | 2011 | 60 | 0.020 |
Why?
| Glycogen Synthase Kinase 3 | 1 | 2011 | 77 | 0.020 |
Why?
| Lipid Peroxidation | 1 | 2011 | 138 | 0.020 |
Why?
| Membranes, Artificial | 1 | 2011 | 67 | 0.020 |
Why?
| NAD | 1 | 2011 | 67 | 0.020 |
Why?
| Acetylation | 1 | 2011 | 212 | 0.020 |
Why?
| Mammals | 1 | 2012 | 251 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 332 | 0.020 |
Why?
| Protein Structure, Secondary | 1 | 2011 | 327 | 0.020 |
Why?
| Transfection | 1 | 2012 | 866 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 934 | 0.020 |
Why?
| In Vitro Techniques | 1 | 2011 | 1044 | 0.020 |
Why?
| Hypoxia | 1 | 2015 | 937 | 0.020 |
Why?
| DNA Breaks, Single-Stranded | 1 | 2009 | 5 | 0.020 |
Why?
| Analysis of Variance | 1 | 2012 | 1226 | 0.020 |
Why?
| Phylogeny | 1 | 2012 | 802 | 0.020 |
Why?
| Evolution, Molecular | 1 | 2012 | 437 | 0.020 |
Why?
| Animal Feed | 1 | 2008 | 50 | 0.020 |
Why?
| NADPH-Ferrihemoprotein Reductase | 1 | 2008 | 10 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1143 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2013 | 1129 | 0.020 |
Why?
| Microsomes, Liver | 1 | 2008 | 57 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2012 | 521 | 0.020 |
Why?
| Caspases | 1 | 2009 | 245 | 0.020 |
Why?
| Oxygen | 1 | 2012 | 839 | 0.020 |
Why?
| Transcription Factor AP-1 | 1 | 2007 | 82 | 0.020 |
Why?
| Tetrazolium Salts | 1 | 2006 | 18 | 0.020 |
Why?
| Mitochondria | 1 | 2012 | 752 | 0.020 |
Why?
| NFATC Transcription Factors | 1 | 2007 | 76 | 0.020 |
Why?
| Indicators and Reagents | 1 | 2006 | 100 | 0.020 |
Why?
| Cell Respiration | 1 | 2006 | 74 | 0.020 |
Why?
| Proteomics | 1 | 2012 | 854 | 0.020 |
Why?
| Thiazoles | 1 | 2006 | 112 | 0.020 |
Why?
| Deoxyuridine | 1 | 2006 | 6 | 0.020 |
Why?
| Cysteine | 1 | 2007 | 173 | 0.020 |
Why?
| Smoke | 1 | 2007 | 133 | 0.020 |
Why?
| Drug Carriers | 1 | 2006 | 113 | 0.020 |
Why?
| Superoxides | 1 | 2006 | 215 | 0.020 |
Why?
| Drug Interactions | 1 | 2006 | 347 | 0.020 |
Why?
| Colonic Neoplasms | 1 | 2006 | 221 | 0.010 |
Why?
| Drug Delivery Systems | 1 | 2006 | 301 | 0.010 |
Why?
| Oxygen Consumption | 1 | 2006 | 572 | 0.010 |
Why?
| Respiratory Tract Infections | 1 | 2007 | 323 | 0.010 |
Why?
| Time Factors | 1 | 2012 | 6186 | 0.010 |
Why?
| Liver | 1 | 2008 | 1693 | 0.010 |
Why?
| Aged | 1 | 2019 | 19296 | 0.010 |
Why?
| Child, Preschool | 1 | 2014 | 9174 | 0.010 |
Why?
| Cytokines | 1 | 2007 | 1857 | 0.010 |
Why?
| Middle Aged | 1 | 2019 | 27080 | 0.010 |
Why?
|
|
Reigan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|